ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Sclerosis (MS) in Berlin, BE

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Multiple Sclerosis
Sclerosis
Relapsing-Remitting Multiple Sclerosis
Chronic Progressive Multiple Sclerosis
Autoimmune Diseases
Cognitive Dysfunction
Neoplasm Metastasis

Multiple Sclerosis (MS) trials near Berlin, BE, DEU:

Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis (NEOS)

Efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis...

Enrolling
Multiple Sclerosis (MS)
Other: Ofatumumab placebo
Drug: Siponimod

Phase 3

Novartis
Novartis

Berlin, Germany and 73 other locations

This study will evaluate the safety, tolerability, and descriptive efficacy of BIIB017 in pediatric participants with relapsing-remitting multiple...

Active, not recruiting
Multiple Sclerosis, Relapsing-Remitting
Drug: Interferon beta type 1a
Drug: BIIB017 (peginterferon beta-1a)

Phase 3

Biogen
Biogen

Berlin, Germany and 64 other locations

study will compare ofatumumab vs. European approved platform first line self-administered disease modifying therapy (DMT) in newly diagnosed MS...

Active, not recruiting
Multiple Sclerosis
Drug: Ofatumumab
Drug: First line DMT

Phase 3

Novartis
Novartis

Berlin, Germany and 40 other locations

Open-label study to evaluate the effectiveness of treatment with ofatumumab in subjects transitioning from any fumarate-based RMS approved therapy or...

Active, not recruiting
Relapsing Multiple Sclerosis
Biological: Ofatumumab

Phase 3

Novartis
Novartis

Potsdam, Germany and 122 other locations

Status recently updated

) neo-antigen in subjects with relapsing multiple sclerosis (RMS).COVID-19 sub-study:The purpose of this research sub-study is to e...

Enrolling
Active, not recruiting
Relapsing Multiple Sclerosis
Biological: 23-valent pneumococcal polysaccharide vaccine (23-PPV)
Biological: Tetanus toxoid (TT) containing vaccine (Td, Tdap)

Phase 3

Novartis
Novartis

Potsdam, Germany and 297 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems